It has previously been reported that the phospholipase A2 inhibitor, ONO‐RS‐082, was able to rescue current through two of six heterozygous TASK‐1 mutations identified in patients with PAH (Ma et al. Here, KCNK3 is linked to pulmonary arterial hypertension.